IL-10 derived from Hepatocarcinoma cells improves human induced regulatory T cells function via JAK1/STAT5 pathway in tumor microenvironment

Mol Immunol. 2021 May:133:163-172. doi: 10.1016/j.molimm.2021.02.014. Epub 2021 Mar 2.

Abstract

Forkhead box P3 (Foxp3) expressing CD4+CD25+ regulatory T cells (Tregs), an essential subset of immune T cells for maintaining immune homeostasis is implicated as a negative regulator in an anti-tumor immune response. Current researches suggest that reducing tumor-infiltrating Tregs contribute to enhanced anti-cancer effect. However, the mechanism of infiltration of a large number of Tregs into tumor tissues is still unclear. In this study, human induced Tregs (iTregs) were co-cultured with human hepatocytes and various types of cancer cells (HepG2, NSCLC, and AsPC-1) supernatants. Foxp3, multiple cytokines, levels of apoptosis and suppressive ability of iTregs were detected by FACS. Western blot was employed to test of proteins. Impact of HepG2 supernatants on T cell subpopulations differentiation, cytokines in supernatants were examed by FACS and ELISA respectively. Anti-IL-10R antibody and JAK1 inhibitor were used to reconfirm the role of tumor-derived IL-10 play in the regulation on iTregs. Hepatocarcinoma cells (HCC) supernatants treatment increases Foxp3 stability and reduces apoptosis level in human iTregs without influencing its differentiation trend. Furthermore, IL-10 was found to be extremely higher in HCC supernatants than other groups, IL-10R blockade neutralize the effect of HCC supernatants on iTregs in vitro obviously. HCC supernatants also reversed IL-1β/6 triggered decline on Foxp3 which may be related to higher expression of JAK1 and elevated phosphorylation level of STAT5 induced by IL-10. Our results suggest that improved stability and abnormal accumulation of Tregs in tumor microenvironment is IL-10/JAK1/STAT5 signal pathway-dependent and provide a novel approach for improving the efficiency of anti-tumor immunotherapy.

Keywords: Foxp3; HCC; IL-10; STAT5; iTregs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Adenoma / pathology
  • Apoptosis / immunology
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cell Line, Tumor
  • Coculture Techniques
  • Culture Media, Conditioned / chemistry
  • Forkhead Transcription Factors / analysis
  • Hep G2 Cells
  • Hepatocytes / metabolism
  • Humans
  • Immunotherapy / methods
  • Interleukin-10 / analysis
  • Interleukin-10 / immunology*
  • Janus Kinase 1 / antagonists & inhibitors
  • Janus Kinase 1 / metabolism*
  • Liver Neoplasms / pathology*
  • Lung Neoplasms / pathology
  • Pancreatic Neoplasms / pathology
  • Receptors, Interleukin-10 / antagonists & inhibitors
  • STAT5 Transcription Factor / metabolism*
  • T-Lymphocytes, Regulatory / immunology*
  • Tumor Microenvironment / immunology*
  • Tumor Suppressor Proteins / metabolism*

Substances

  • Culture Media, Conditioned
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • IL10 protein, human
  • Receptors, Interleukin-10
  • STAT5 Transcription Factor
  • STAT5A protein, human
  • Tumor Suppressor Proteins
  • Interleukin-10
  • JAK1 protein, human
  • Janus Kinase 1

Supplementary concepts

  • Pancreatic adenoma